表皮生长因子受体抑制剂用于肺癌治疗的最新研究进展

耿传荣,邓玉晓,崔新强,赵思太,冯光玲,孙晋瑞,段崇刚

中国药学杂志 ›› 2018, Vol. 53 ›› Issue (13) : 1037-1046.

PDF(3077 KB)
中国药学杂志
PDF(3077 KB)
中国药学杂志 ›› 2018, Vol. 53 ›› Issue (13) : 1037-1046. DOI: 10.11669/cpj.2018.13.001
综述

表皮生长因子受体抑制剂用于肺癌治疗的最新研究进展

  • 耿传荣,邓玉晓,崔新强,赵思太,冯光玲,孙晋瑞,段崇刚*
作者信息 +

Advance in the Research of Epidermal Growth Factor Receptor Inhibitors Related to Lung Cancer

  • GENG Chuan-rong, DENG Yu-xiao, CUI Xin-qiang, ZHAO Si-tai, FENG Guang-ling, SUN Jin-rui, DUAN Chong-gang*
Author information +
文章历史 +

摘要

表皮生长因子受体(EGFR)属于蛋白酪氨酸激酶受体超家族一员,在肿瘤细胞生长、凋亡、侵袭和转移中具有重要作用。靶向EGFR 酪氨酸激酶抑制剂已经成为抗肿瘤药物研究的热点和趋势。目前靶向EGFR酪氨酸激酶小分子抑制剂研究有了长足进展,开发出一系列具有临床应用价值的药物分子,但是大多数病人在治疗后期会因为受体氨基酸的激活突变而导致耐药性。因此对于适用于后期治疗或者可以满足长期治疗效果的药物依然是临床急需。笔者通过查阅近20年来国内、外有关文献,详细介绍靶向小分子EGFR酪氨酸激酶抑制剂的研究进展和抗肿瘤机制,为更加深入研究提供参考依据。

Abstract

Epidermal growth factor receptor (EGFR), a member of the super family of protein tyrosine kinase receptors, plays a crucial role in proliferation, apoptosis, aggression and metastasis of tumor cells. The target-EGFR inhibitors have been a hotspot and tendency in the progress of anti-tumors. Currently, the target-EGFR inhibitors have made a steady progress and many valuable drugs in the clinical treatment have been developed. However, many patients will be resistance to the drugs due to the mutation of amino acid. Therefore, drugs which can be effective in the later treatment or long-term therapies will always be deficient. In this article, the research progress and mechanism of anti-tumor of small molecules EGFR inhibitors in detail are reviewed.

关键词

表皮生长因子受体 / 抑制剂 / 抗肿瘤 / 突变 / 耐药性

Key words

epidermal growth factor receptor / inhibitor / anti-tumor / mutation / drug resistance

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
耿传荣,邓玉晓,崔新强,赵思太,冯光玲,孙晋瑞,段崇刚. 表皮生长因子受体抑制剂用于肺癌治疗的最新研究进展[J]. 中国药学杂志, 2018, 53(13): 1037-1046 https://doi.org/10.11669/cpj.2018.13.001
GENG Chuan-rong, DENG Yu-xiao, CUI Xin-qiang, ZHAO Si-tai, FENG Guang-ling, SUN Jin-rui, DUAN Chong-gang. Advance in the Research of Epidermal Growth Factor Receptor Inhibitors Related to Lung Cancer[J]. Chinese Pharmaceutical Journal, 2018, 53(13): 1037-1046 https://doi.org/10.11669/cpj.2018.13.001
中图分类号： R965   

参考文献

[1] CHONG C R, JANNE P A. The quest to overcome resistance to EGFR-targeted therapies in cancer[J]. Nat Med, 2013, 19(11):1389-1400.
[2] CIARDIELLO F, TORTORA G. EGFR Antagonists in cancer treatment[J]. N Engl J Med, 2008, 358(11):1160-1174.
[3] TEBBUTT N, PEDERSEN M W, JOHNS T G. Targeting the ERBB family in cancer: couples therapy[J]. Nat Rev Cancer, 2013, 13(9):663-673.
[4] HE W L X. Advance in the research of small molecules EGFR tyrosine kinase inhibitors[J]. Chin Pharm J (中国药学杂志), 2007, 42(22):1685-1688.
[5] GOSS G, SPAANS J. Epidermal growth factor receptor inhibition in the management of squamous cell carcinoma of the lung[J]. Oncologist, 2016,21(2):205-213.
[6] CHENG H, NAIR S K, MURRAY B W, et al. Discovery PF-06459988, a potent, WT sparing, irreversible inhibitor of T790M-containing EGFR mutants[J]. J Med Chem, 2016, 59(5):2005-2024.
[7] KOBAYASHI K, HAGIWARA K. Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)[J]. Target Oncol, 2013, 8(1):27-33.
[8] MAKOTO M, AKIRA I, KUNIHIKO K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J]. N Engl J Med, 2010, 362(25):2380-2388.
[9] BONOMI P. Erlotinib: a new therapeutic approach for non-small cell lung cancer[J]. Expert Opin Inv Drug, 2003, 12(8):1395-1401.
[10] GAN H K, SERUGA B, KNOX J J. Sunitinib in solid tumors[J]. Expert Opin Inv Drug, 2009, 18(6):821-834.
[11] HIGA G M, ABRAHAM J. Lapatinib in the treatment of breast cancer[J]. Expert Rev Anticancer, 2007, 7(9):1183-1192.
[12] ZIVI A, CERBONE L, RECINE F, et al. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma[J]. Expert Opi Drug Saf, 2012, 11(5):851-859.
[13] SHI Y, ZHANG L, LIU X, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN):a randomised, double-blind phase 3 non-inferiority trial[J]. Lancet Oncol, 2013, 14(10):953-961.
[14] MARTIN P, OLIVER S, KENNEDY S J, et al. Pharmacokinetics of vandetanib: three phase Ⅰ studies in healthy subjects[J]. Clin Ther, 2011, 34(1):221-237.
[15] PEMOVSKA T, JOHNSON E, KONTRO M, et al. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation[J]. Nature, 2015, 519:102-105.
[16] O′HARE T, SHAKESPEARE W C, ZHU X, et al. AP24534, a Pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance[J]. Cancer Cell, 2009, 16(5):401-412.
[17] KOBAYASHI Y, TOGASHI Y, YATABE Y, et al. EGFR Exon 18 mutations in lung cancer: molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first- or third-generation TKIs[J]. Clin Cancer Res, 2015, 21(23):5305-5313.
[18] MI Y J, LIANG Y J, HUANG H B, et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters[J]. Cancer Res, 2010, 70(20):7981-7991.
[19] POPAT S, MELLEMGAARD A, FAHRBACH K, et al. Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network Meta-analysis[J]. Future Oncol, 2014, 11(3):409-420.
[20] HE H H L, XU Y. Osimertinib: a new drug for non-small cell lung cancer[J]. Chin J New Drug (中国新药杂志), 2016, 25(16):1801-1806.
[21] MATSUI J, FUNAHASHI Y, UENAKA T, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase[J]. Clin Cancer Res, 2008, 14(17):5459-5465.
[22] PASSARO A, GUERINI-ROCCO E, POCHESCI A, et al. Targeting EGFR T790M mutation in NSCLC: from biology to evaluation and treatment[J]. Pharm Res, 2017, 117(Suppl C):406-415.
[23] UCHIBORI K, INASE N, ARAKI M, et al. Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer[J]. Nat Comm, 2017, 8(14):14768-14784.
[24] WEISBERG E, BOULTON C, KELLY L M, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412[J]. Cancer Cell, 2002, 1(5):433-443.
[25] CARTER C A, KELLY R J, GIACCONE G. Small-molecule inhibitors of the human epidermal receptor family[J]. Expert Opin Inv Drug, 2009, 18(12):1829-1842.
[26] DOWELL J E, MINNA J D. The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy[J]. Nat Clin Prac Oncol, 2004, 1(1):2-3.
[27] YARDEN Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities[J]. Eur J Cancer, 2001, 37(4):3-8.
[28] BLUME-JENSEN P, HUNTER T. Oncogenic kinase signaling[J]. Nature, 2001, 411(6835):355-365.
[29] TERECH P, OSTUNI E, WEISS R G. Structural study of cholesteryl anthraquinone-2-carboxylate (CAQ) physical organogels by neutron and X-ray small angle scattering[J]. J Phys Chem, 1996, 100(9):3759-3766.
[30] CHEN R H, YE L B, YUAN P. The research of synthesis of gefitinib[J]. Chin Pharm J (中国药学杂志), 2012, 47(13):1084-1087.
[31] PAEZ J G, J NNE P A, LEE J C, et al. EGFR Mutations in lung cancer correlation with clinical response to gefitinib therapy[J]. Science, 2004, 304(5676):1497-1500.
[32] DOWELL J, MINNA J D, KIRKPATRICK P. Erlotinib hydrochloride[J]. Nat Rev Drug Dis, 2005, 4(1):13-14.
[33] KITANO Y, SUZUKI T, KAWAHARA E, et al. Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors[J]. Bioorg Med Chem Lett, 2007, 17(21):5863-5867.
[34] SONG Z, GE Y, WANG C, et al. Challenges and perspectives on the development of small-molecule EGFR inhibitors against T790M-mediated resistance in non-small-cell lung cancer[J]. J Med Chem, 2016, 59(14):6580-6594.
[35] CHILIN A, CONCONI M T, MARZARO G, et al. Exploring epidermal growth factor receptor (EGFR) inhibitor features: the role of fused dioxygenated rings on the quinazoline scaffold[J]. J Med Chem, 2010, 53(4):1862-1866.
[36] MISHANI E, ABOURBEH G, ROZEN Y, et al. Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors[J]. Nucl Med Biol, 2004, 31(4):469-476.
[37] VAN DER STEEN N, CAPARELLO C, ROLFO C, et al. New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?[J]. Onco Targets Ther, 2016,9(802):6065-6074.
[38] LIU S L M H, CUI Y, ET A L. Osimertinib mesylate-the third generation EGFR inhibitor[J]. Prog Pharm Sci (药学进展), 2016, 40(1):74-80.
[39] CHANG S, ZHANG L, XU S, et al. Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine790→methionine790 mutant[J]. J Med Chem, 2012, 55(6):2711-2723.
[40] CHENG H, NAIR S K, MURRAY B W, et al. Discovery (PF-06459988), a potent, WT sparing, irreversible inhibitor of T790M-containing EGFR mutants[J]. J Med Chem, 2016, 59(5):2005-2024.
[41] ZHOU W, LIU X, TU Z. Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant[J]. J Med Chem, 2013, 56(20):7821-7837.
[42] GUNTHER M, JUCHUM M, KELTER G, et al. Lung cancer: EGFR inhibitors with low nanomolar activity against a therapy-resistant L858R/T790M/C797S mutant[J]. Angewand Chem, 2016, 55(36):10890-10894.
[43] JIA Y, YUN C H, PARK E, et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors[J]. Nature, 2016, 534(7605):129-132.
PDF(3077 KB)

Accesses

Citation

Detail
段落导航
相关文章

/

〈 〉